the fy19 defense appropriation provides $6 million (m) to the department of defense tuberous sclerosis complex research program (tscrp) to support innovative, high-impact tsc research.  as directed by the office of the assistant secretary of defense for health affairs, the defense health agency, j9 research and development directorate manages the defense health program (dhp) research, development, test, and evaluation (rdt&e) appropriation.  the managing agent for the anticipated program announcements/funding opportunities is the congressionally directed medical research programs (cdmrp) at the u.s. army medical research and materiel command (usamrmc).

fy19 tscrp program announcements and general application instructions for the following award mechanisms are posted on the grants.gov website. 

focus areas:  the goal of the fy19 tscrp is to fund exploratory, pioneering, and transformative science that promotes discoveries in tuberous sclerosis complex (tsc), from mechanistic insights to clinical application, by supporting new ideas and investigators for the benefit of service members, their beneficiaries, and the american public.  within this context, the fy19 tscrp encourages applications that address the critical needs of the tsc community in one or more of the following fy19 focus areas:

• eradicating tumors associated with tsc and tsc-associated lymphangioleiomyomatosis (lam), including gaining a deeper mechanistic understanding of tsc signaling pathways
• preventing epilepsy, improving treatment, and mitigating comorbidities associated with tsc-related seizures
• understanding the features of tsc-associated neuropsychiatric disorders (tand) and reducing their impact through pharmacological or nonpharmacological interventions
• advancing clinical trial readiness through development of biomarkers, clinical endpoints, clinical pharmacokinetic/pharmacodynamic (pk/pd), patient selection and sample size determination, novel drug delivery, and treatment optimization

https://cdmrp.army.mil/funding/tscrp

submission deadline extension

exploration – hypothesis development award – letter of intent due july 9, 2019

• investigators at all academic levels (or equivalent), including postdoctoral fellows
• supports the initial exploration of innovative, high-risk, high gain, and potentially groundbreaking concepts in the tsc research field.
• projects involving human subjects or human biological substances must be exempt under 32 cfr 219.101(b)(4) or eligible for expedited review under 32 cfr 219.110 or 21 cfr 56.110.
• preliminary data are not required.
• clinical trials not allowed.
• the maximum allowable funding for the entire period of performance is $150,000 in direct costs.
• indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.
• maximum period of performance is 2 year

idea development award – letter of intent due july 9, 2019

established investigators:  independent investigators at or above the level of assistant professor (or equivalent);

or

new investigators:  independent investigator at or below the level of assistant professor (or equivalent); or established independent investigator in an area other than tsc at or above the level of assistant professor seeking to transition to a career in tsc.

• supports ideas that have the potential to yield high-impact findings and new avenues of investigation.
• preliminary data are expected.
• clinical trials not allowed.
• new investigator option supports the continued development of promising independent investigators that are early in their faculty appointments and/or the transition of established investigators from other research fields into a career in tsc research.
• applications from new investigators and established investigators will be peer and programmatically reviewed separately
• the maximum allowable funding for the entire period of performance is $450,000 for direct costs.
• indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.
• maximum period of performance is 3 years

clinical translational research award – letter of intent due july 9, 2019

• independent investigators at or above the level of assistant professor (or equivalent)
• supports studies that will move promising, well-founded preclinical and/or clinical research findings closer to clinical application, including, diagnosis, prognosis, or treatment of tsc.
• studies advancing clinical trial readiness through development of biomarkers, clinical endpoints, and validation of pk/pd are of particular interest.
• preference will be given to studies that involve human samples, patients, or leverage existing clinical data and/or ongoing clinical studies. 
• preclinical studies may be appropriate but must include a clinical component.
• applications may include a small, pilot clinical trial intended to inform the next step in the continuum of translational research.
• projects that are exploratory and/or strictly animal research will not be considered for funding.
• preliminary data required.
• the maximum allowable funding for the entire period of performance is $600,000 in direct costs.
• indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.
• maximum period of performance is 3 years

a pre-application is required and must be submitted through the electronic biomedical research application portal (ebrap) at https://ebrap.org prior to the pre-application deadline.  all applications must conform to the final program announcements and general application instructions available for electronic downloading from the grants.gov website.  the application package containing the required forms for each award mechanism is also be found on grants.gov.  a listing of all cdmrp and other usamrmc extramural funding opportunities can be obtained on the grants.gov website by performing a basic search using cfda number 12.420. 

for email notification when program announcements are released, subscribe to program-specific news and updates under “email subscriptions” on the ebrap homepage at https://ebrap.org.  for more information about the tscrp or other cdmrp-administered programs, please visit the cdmrp website (https://cdmrp.army.mil).

point of contact:

cdmrp help desk
301-682-5507
help@ebrap.org

dear members of the 5g community,

oce is pleased to let you know that intake is now open for a new encqor 5g academic technology development challenge statement.

launched earlier this year, the encqor 5g academic technology development program partners researchers at ontario-based post secondary institutions with encqor 5g anchor firms on 5g technology development projects. areas of research interest are defined by challenge statements submitted to oce by the encqor 5g anchor firms and posted to the oce website on a rolling basis.

the new challenge statement is listed in the table below.

briefly, this award aims to recognize an outstanding publication by a canadian researcher in the field of spinal cord and brain injury research (including concussion) in the last two years (january 1, 2017 to march 31, 2019) with a $50,000 prize. applicants will need to demonstrate that their publication includes novel and ground-breaking results that represent a major advancement for the research area and has the potential to generate new hypotheses. the award is open to all active investigators in any phase of their career, graduate 世界杯2022赛程表淘汰赛 , and postdoctoral fellows conducting research at a canadian institution. 

the deadline for receipt of applications is may 20, 2019 (16:00-est). please refer to the request for applications for additional details (https://braincanada.ca/for-researchers/), and we encourage all eligible applicants to contact programs@braincanada.ca with any additional questions.

briefly, this award aims to recognize an outstanding publication by a canadian researcher in the field of spinal cord and brain injury research (including concussion) in the last two years (january 1, 2017 to march 31, 2019) with a $50,000 prize. applicants will need to demonstrate that their publication includes novel and ground-breaking results that represent a major advancement for the research area and has the potential to generate new hypotheses. the award is open to all active investigators in any phase of their career, graduate 世界杯2022赛程表淘汰赛 , and postdoctoral fellows conducting research at a canadian institution. 

the deadline for receipt of applications is may 20, 2019 (16:00-est). please refer to the request for applications for additional details (https://braincanada.ca/for-researchers/), and we encourage all eligible applicants to contact programs@braincanada.ca with any additional questions.

the national call for proposals 2019 part 2: research, capacity-building, and coordination services (indirect)

immigration, refugees and citizenship canada (ircc) administers the settlement program to help newcomers settle and adapt to life in canada, setting them on a path to integration and full citizenship. ircc works with many partners to deliver a set of ongoing high-quality services to newcomers.

call for proposals part 2 (cfp 2) is a follow-up funding process to the national call for proposals 2019 for the settlement and resettlement assistance programs. this process is for settlement program services which were not included in the call for proposals 2019. this process does not include the resettlement assistance program.

the purpose of this cfp 2 is to complement direct settlement services across canada by funding projects which promote research, capacity-building and coordination services. funding for recommended projects will commence on april 1, 2020 and will be eligible for a duration of up to five (5) years, ending no later than march 31, 2025. these funding guidelines are a tool to help applicants develop their proposal(s). all applicants are responsible for reading the funding guidelines in full.

applicants applying to receive settlement program funding for base indirect services can propose customized services to address specific gaps or current needs as identified in the customized services section of these guidelines. customized services are enhanced, refined or niche areas in which ircc would like to see expansion, or customization, in response to emerging or specific sector needs. the priorities outlined in these guidelines are based on valuable input gathered through extensive local consultations with settlement, resettlement and other stakeholders across all regions.  they also align closely with the priorities identified in the first call for proposals 2019.

research projects that foster collaboration between settlement sector organizations (settlement service providers, umbrella organizations, coordinating bodies, lips and/or rifs); and conferences and academic research to leverage evidence, identify research gaps, and support locally-grounded research that is also relevant on a national or regional scale.

he fy19 defense appropriation provides $5 million (m) to the department of defense tick-borne disease research program (tbdrp) to support innovative, high-impact tick-borne disease research. as directed by the office of the assistant secretary of defense for health affairs, the defense health agency j9, research and development directorate manages the defense health program (dhp) research, development, test, and evaluation (rdt&e) appropriation. the managing agent for the anticipated program announcements/funding opportunities is the congressionally directed medical research programs (cdmrp) at the u.s. army medical research and materiel command (usamrmc).

fy19 tbdrp program announcements and general application instructions for the following award mechanisms are posted on the grants.gov website.

applications submitted to the fy19 tbdrp must address at least one of the following specific focus areas in lyme disease and other tick-borne diseases:

• diagnosis
  • accurate diagnostics and biomarkers for lyme disease and co-infections and/or other tick-borne diseases
  • diagnostic biomarkers for lyme disease that distinguish between active infection and previous exposure, and/or monitor response to treatment
• pathogenesis
  • pathogenic mechanisms, including immune protection, for lyme disease, other tick-borne diseases, and/or co-infections
  • complex biology of lyme borrelia in the host (beyond in vitro studies), including its survival, evasion of the host immune system, and subversion of the effectiveness of antibiotics
  • underlying mechanisms of persistent symptoms associated with lyme disease
• prevention
  • safe and effective human vaccines for tick-borne diseases
  • identification, validation, and/or improvement of tick-targeted prevention and control interventions
  • ecology of understudied tick-borne disease vectors and reservoirs with emphasis on how it relates to human risk.
• treatment
  • antibiotic combinations and/or therapeutic options for treating acute and persistent illness

https://cdmrp.army.mil/funding/tbdrp

investigator-initiated research award – preproposal; due may 22, 2017

• independent investigators at or above the level of assistant professor (or equivalent)
• to fund highly rigorous, high-impact studies that have the potential to make important contributions to lyme disease and other tick-borne disease research, patient care, and/or quality of life.
• applications should articulate both the short- and long-term impact of the proposed research, as well as the public health burden of the disease being addressed.
• preliminary or published data to support feasibility are required.
• promotes any phase of research from basic through translational, including preclinical studies in animal models or human subjects, as well as correlative studies associated with an existing clinical trial to establish proof-of-principle for further development in future studies; however, clinical trials are not allowed.
• maximum funding of $650k for direct costs (plus indirect costs)
• maximum period of performance is 3 years

idea award – preproposal due may 22, 2019

• independent investigators at or above the level of assistant professor (or equivalent)
• to fund conceptually innovative, high-risk/potentially high-reward research in the early stages of development that could lead to critical discoveries or major advancements that will accelerate progress in improving outcomes for individuals affected by lyme disease and/or other tick-borne illnesses.
• applications should articulate the qualities that make the research innovative (not merely an incremental advance), as well as the public health burden of the disease being addressed.
• preliminary data that are relevant to the proposed research project are encouraged, but not required.
• clinical trials are not allowed.
• maximum funding of $300k for direct costs (plus indirect costs)
• maximum period of performance is 2 years

career development award – letter of intent due may 22, 2019

• principal investigator (pi): 
• early-career research scientist or physician scientist within 10 years of completing terminal degree (excluding time in residency or on family medical leave) at the time of submission, working to become independent investigators who exhibit a strong desire to pursue careers in tick-borne disease research; time spent as a postdoctoral fellow is not excluded
• mentor:  independent investigators at or above the level of associate professor (or equivalent); must have a proven funding and publication record in tick-borne disease research
• the pi and mentor do not need to be located at the same organization.
• to fund early-career investigators to conduct impactful research under the mentorship of an experienced tick-borne disease researcher.
• career development plan is required.  plan should be prepared with appropriate guidance from the mentor, should clearly articulate a strategy for acquiring the necessary skills, competence, and expertise to establish a career at the forefront of tick-borne disease research, and should outline how the pi will gain experience in tick-borne disease research.  pi’s institution must demonstrate a commitment to the pi through a minimum of 75% protected time for tick-borne disease research.
• preliminary data are not; however, logical reasoning and a sound scientific rationale for the proposed research must be demonstrated.
• clinical trials are not allowed.
• maximum funding of $250k for direct costs (plus indirect costs)
• maximum period of performance is 3 years

a pre-application is required and must be submitted through the electronic biomedical research application portal (ebrap) at https://ebrap.org prior to the pre-application deadline.  all applications must conform to the final program announcements and general application instructions available for electronic downloading from the grants.gov website.  the application package containing the required forms for each award mechanism will also be found on grants.gov.  a listing of all cdmrp funding opportunities can be obtained on the grants.gov website by performing a basic search using cfda number 12.420.

for email notification when program announcements are released, subscribe to program-specific news and updates under “email subscriptions” on the ebrap homepage at https://ebrap.org/.  for more information about the tbdrp or other cdmrp-administered programs, please visit the cdmrp website (https://cdmrp.army.mil/).

point of contact:

cdmrp help hesk
301-682-5507
help@ebrap.org

this call for proposals is dedicated to the design and construction of low-cost, resilient, energy efficient, and safe housing for first nations communities, an area of immediate and high priority for ic-impacts.

your proposal must reflect the principles of equity, diversity, and inclusion in order to increase equity and enhance research excellence. ic-impacts is committed to the principles of equity, diversity, and inclusion, adopted from nserc’s statement on equity, diversity, and excellence in natural sciences and engineering research.